Share Price and Basic Stock Data
Last Updated: December 17, 2025, 10:38 pm
| PEG Ratio | 0.54 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Adeshwar Meditex Ltd operates in the medical equipment and accessories sector, with its stock price currently at ₹16.6 and a market capitalization of ₹23.9 Cr. The company has shown a fluctuating but generally upward trend in sales over recent years. For instance, it reported sales of ₹58.60 Cr in March 2018, which rose to ₹82.36 Cr by March 2023. However, sales slightly declined to ₹79.85 Cr in March 2024 before rebounding to ₹83.71 Cr in March 2025. Quarterly sales figures also reflect this volatility; the latest quarter ending September 2023 recorded sales of ₹46.26 Cr, a notable increase from ₹34.54 Cr in March 2022. The sales growth trajectory indicates a recovery post-pandemic, although the company has faced challenges in maintaining consistent revenue growth in some quarters.
Profitability and Efficiency Metrics
The profitability metrics of Adeshwar Meditex Ltd highlight a mixed performance, with an operating profit margin (OPM) of 5.82% as of the latest reporting period. The operating profit stood at ₹4.42 Cr for the fiscal year ending March 2025, compared to ₹5.22 Cr in March 2023. The net profit for the same period was ₹2.07 Cr, reflecting a stable performance relative to ₹2.01 Cr in March 2024. The return on equity (ROE) was reported at 5.51%, while the return on capital employed (ROCE) stood at 8.27%. The cash conversion cycle (CCC) of 175.13 days indicates a longer-than-typical duration for converting investments into cash flows, which may signal inefficiencies in inventory management or receivables collection within the sector.
Balance Sheet Strength and Financial Ratios
Adeshwar Meditex Ltd’s balance sheet shows a cautious approach to debt management, with total borrowings reduced to ₹6.10 Cr as of September 2025, down from ₹22.45 Cr in March 2021. The company holds reserves of ₹23.26 Cr, which provides a buffer against liabilities. The current ratio is a healthy 2.03, indicating good short-term financial stability. However, the debt-to-equity ratio of 0.33 suggests that while leverage is low, it could also imply underutilization of borrowing potential for growth. The price-to-book value (P/BV) ratio stands at 0.65x, indicating that the market may undervalue the stock relative to its book value, which could attract value-focused investors. Overall, the balance sheet reflects a conservative financial strategy with a focus on maintaining liquidity.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Adeshwar Meditex Ltd reveals a significant level of promoter ownership at 57.55%, indicating strong control by the founding members. Public shareholding stands at 42.44%, with the number of shareholders reported at 187 as of September 2025. This distribution suggests a stable base of retail investors, although foreign institutional investors (FIIs) and domestic institutional investors (DIIs) are not represented, which may limit institutional interest in the stock. The fluctuating promoter shareholding from 58.45% in June 2021 to the current level may raise questions about management confidence. However, the large promoter stake may also reassure retail investors regarding the long-term vision and commitment of the management team.
Outlook, Risks, and Final Insight
Looking ahead, Adeshwar Meditex Ltd faces both opportunities and challenges. The company’s revenue recovery trajectory and stable profitability metrics provide a solid foundation for future growth. However, risks include the prolonged cash conversion cycle, which could impact liquidity and operational efficiency. Additionally, the absence of institutional backing may limit the stock’s appeal to larger investors. Should the company enhance its operational efficiencies and manage its working capital better, it could unlock value for shareholders. Conversely, continued volatility in sales and profitability could deter potential investors. The balance of these factors will be crucial in determining the company’s ability to leverage its strong market position in the medical equipment sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Constronics Infra Ltd | 77.7 Cr. | 62.0 | 123/46.0 | 17.6 | 32.8 | 0.00 % | 19.7 % | 15.8 % | 10.0 |
| Centenial Surgical Suture Ltd | 38.2 Cr. | 105 | 189/82.2 | 84.1 | 0.00 % | 3.94 % | 4.64 % | 10.0 | |
| Adeshwar Meditex Ltd | 23.9 Cr. | 16.6 | 26.5/14.0 | 11.5 | 26.1 | 0.00 % | 8.27 % | 5.51 % | 10.0 |
| Poly Medicure Ltd | 17,807 Cr. | 1,757 | 2,938/1,740 | 49.2 | 288 | 0.20 % | 20.1 % | 15.8 % | 5.00 |
| Mohini Health & Hygiene Ltd | 72.9 Cr. | 40.0 | 86.9/37.9 | 21.8 | 55.7 | 0.00 % | 14.1 % | 10.0 % | 10.0 |
| Industry Average | 17,807.00 Cr | 396.12 | 25.03 | 97.34 | 0.04% | 13.22% | 10.35% | 9.00 |
Quarterly Result
| Metric | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 36.53 | 29.45 | 30.21 | 34.54 | 46.06 | 36.30 | 46.26 | 33.59 | 40.90 | 37.45 | 30.06 |
| Expenses | 34.90 | 26.47 | 28.12 | 33.25 | 43.33 | 33.84 | 44.05 | 30.61 | 38.90 | 35.27 | 28.52 |
| Operating Profit | 1.63 | 2.98 | 2.09 | 1.29 | 2.73 | 2.46 | 2.21 | 2.98 | 2.00 | 2.18 | 1.54 |
| OPM % | 4.46% | 10.12% | 6.92% | 3.73% | 5.93% | 6.78% | 4.78% | 8.87% | 4.89% | 5.82% | 5.12% |
| Other Income | 0.09 | 0.17 | 0.02 | 0.21 | 0.08 | 0.22 | 0.08 | 0.05 | 0.21 | 0.17 | 0.05 |
| Interest | 1.08 | 1.11 | 1.02 | 1.01 | 1.04 | 1.01 | 1.03 | 0.90 | 0.71 | 0.31 | 0.36 |
| Depreciation | 0.17 | 0.17 | 0.17 | 0.22 | 0.26 | 0.27 | 0.29 | 0.31 | 0.25 | 0.21 | 0.21 |
| Profit before tax | 0.47 | 1.87 | 0.92 | 0.27 | 1.51 | 1.40 | 0.97 | 1.82 | 1.25 | 1.83 | 1.02 |
| Tax % | 29.79% | 27.27% | 26.09% | 59.26% | 27.81% | 29.29% | 25.77% | 29.12% | 28.00% | 27.32% | 28.43% |
| Net Profit | 0.33 | 1.36 | 0.68 | 0.11 | 1.09 | 0.99 | 0.73 | 1.28 | 0.90 | 1.34 | 0.73 |
| EPS in Rs | 0.63 | 1.29 | 0.47 | 0.08 | 0.76 | 0.69 | 0.51 | 0.89 | 0.62 | 0.93 | 0.51 |
Last Updated: December 28, 2025, 9:01 am
Below is a detailed analysis of the quarterly data for Adeshwar Meditex Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 30.06 Cr.. The value appears to be declining and may need further review. It has decreased from 37.45 Cr. (Mar 2025) to 30.06 Cr., marking a decrease of 7.39 Cr..
- For Expenses, as of Sep 2025, the value is 28.52 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 35.27 Cr. (Mar 2025) to 28.52 Cr., marking a decrease of 6.75 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.54 Cr.. The value appears to be declining and may need further review. It has decreased from 2.18 Cr. (Mar 2025) to 1.54 Cr., marking a decrease of 0.64 Cr..
- For OPM %, as of Sep 2025, the value is 5.12%. The value appears to be declining and may need further review. It has decreased from 5.82% (Mar 2025) to 5.12%, marking a decrease of 0.70%.
- For Other Income, as of Sep 2025, the value is 0.05 Cr.. The value appears to be declining and may need further review. It has decreased from 0.17 Cr. (Mar 2025) to 0.05 Cr., marking a decrease of 0.12 Cr..
- For Interest, as of Sep 2025, the value is 0.36 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.31 Cr. (Mar 2025) to 0.36 Cr., marking an increase of 0.05 Cr..
- For Depreciation, as of Sep 2025, the value is 0.21 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.21 Cr..
- For Profit before tax, as of Sep 2025, the value is 1.02 Cr.. The value appears to be declining and may need further review. It has decreased from 1.83 Cr. (Mar 2025) to 1.02 Cr., marking a decrease of 0.81 Cr..
- For Tax %, as of Sep 2025, the value is 28.43%. The value appears to be increasing, which may not be favorable. It has increased from 27.32% (Mar 2025) to 28.43%, marking an increase of 1.11%.
- For Net Profit, as of Sep 2025, the value is 0.73 Cr.. The value appears to be declining and may need further review. It has decreased from 1.34 Cr. (Mar 2025) to 0.73 Cr., marking a decrease of 0.61 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.51. The value appears to be declining and may need further review. It has decreased from 0.93 (Mar 2025) to 0.51, marking a decrease of 0.42.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:19 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 58.60 | 52.92 | 56.12 | 65.97 | 64.76 | 82.36 | 79.85 | 83.71 | 67.51 |
| Expenses | 52.96 | 47.44 | 50.64 | 61.22 | 61.39 | 77.14 | 74.66 | 79.29 | 63.79 |
| Operating Profit | 5.64 | 5.48 | 5.48 | 4.75 | 3.37 | 5.22 | 5.19 | 4.42 | 3.72 |
| OPM % | 9.62% | 10.36% | 9.76% | 7.20% | 5.20% | 6.34% | 6.50% | 5.28% | 5.51% |
| Other Income | 0.10 | 0.25 | 0.28 | 0.13 | 0.23 | 0.31 | 0.13 | 0.26 | 0.22 |
| Interest | 1.78 | 2.23 | 2.52 | 2.19 | 2.03 | 2.09 | 1.93 | 1.39 | 0.67 |
| Depreciation | 0.36 | 0.35 | 0.34 | 0.35 | 0.38 | 0.53 | 0.60 | 0.50 | 0.42 |
| Profit before tax | 3.60 | 3.15 | 2.90 | 2.34 | 1.19 | 2.91 | 2.79 | 2.79 | 2.85 |
| Tax % | 29.72% | 28.25% | 27.24% | 28.63% | 33.61% | 28.52% | 27.96% | 26.16% | |
| Net Profit | 2.54 | 2.26 | 2.12 | 1.68 | 0.79 | 2.07 | 2.01 | 2.07 | 2.07 |
| EPS in Rs | 5.10 | 4.54 | 4.03 | 1.60 | 0.55 | 1.43 | 1.39 | 1.43 | 1.44 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -11.02% | -6.19% | -20.75% | -52.98% | 162.03% | -2.90% | 2.99% |
| Change in YoY Net Profit Growth (%) | 0.00% | 4.83% | -14.56% | -32.22% | 215.00% | -164.92% | 5.88% |
Adeshwar Meditex Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 9% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | 36% |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -10% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 6% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 2:06 pm
Balance Sheet
Last Updated: December 10, 2025, 3:44 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.98 | 4.98 | 5.27 | 10.53 | 14.43 | 14.43 | 14.43 | 14.43 | 14.43 |
| Reserves | 8.55 | 10.81 | 13.64 | 10.05 | 16.52 | 18.48 | 20.48 | 22.53 | 23.26 |
| Borrowings | 11.58 | 19.92 | 21.32 | 22.45 | 18.99 | 16.43 | 13.89 | 12.45 | 6.10 |
| Other Liabilities | 7.33 | 5.79 | 14.57 | 19.27 | 22.63 | 17.67 | 15.23 | 22.79 | 18.91 |
| Total Liabilities | 32.44 | 41.50 | 54.80 | 62.30 | 72.57 | 67.01 | 64.03 | 72.20 | 62.70 |
| Fixed Assets | 2.36 | 2.44 | 2.28 | 2.24 | 3.03 | 3.70 | 3.53 | 2.95 | 2.81 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.02 | 0.04 | 0.08 | 0.08 | 0.10 | 0.10 | 0.10 | 0.00 | 0.00 |
| Other Assets | 30.06 | 39.02 | 52.44 | 59.98 | 69.44 | 63.21 | 60.40 | 69.25 | 59.89 |
| Total Assets | 32.44 | 41.50 | 54.80 | 62.30 | 72.57 | 67.01 | 64.03 | 72.20 | 62.70 |
Below is a detailed analysis of the balance sheet data for Adeshwar Meditex Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.43 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.43 Cr..
- For Reserves, as of Sep 2025, the value is 23.26 Cr.. The value appears strong and on an upward trend. It has increased from 22.53 Cr. (Mar 2025) to 23.26 Cr., marking an increase of 0.73 Cr..
- For Borrowings, as of Sep 2025, the value is 6.10 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 12.45 Cr. (Mar 2025) to 6.10 Cr., marking a decrease of 6.35 Cr..
- For Other Liabilities, as of Sep 2025, the value is 18.91 Cr.. The value appears to be improving (decreasing). It has decreased from 22.79 Cr. (Mar 2025) to 18.91 Cr., marking a decrease of 3.88 Cr..
- For Total Liabilities, as of Sep 2025, the value is 62.70 Cr.. The value appears to be improving (decreasing). It has decreased from 72.20 Cr. (Mar 2025) to 62.70 Cr., marking a decrease of 9.50 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2.81 Cr.. The value appears to be declining and may need further review. It has decreased from 2.95 Cr. (Mar 2025) to 2.81 Cr., marking a decrease of 0.14 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 59.89 Cr.. The value appears to be declining and may need further review. It has decreased from 69.25 Cr. (Mar 2025) to 59.89 Cr., marking a decrease of 9.36 Cr..
- For Total Assets, as of Sep 2025, the value is 62.70 Cr.. The value appears to be declining and may need further review. It has decreased from 72.20 Cr. (Mar 2025) to 62.70 Cr., marking a decrease of 9.50 Cr..
Notably, the Reserves (23.26 Cr.) exceed the Borrowings (6.10 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.94 | -14.44 | -15.84 | -17.70 | -15.62 | -11.21 | -8.70 | -8.03 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 108.69 | 134.63 | 181.26 | 150.82 | 183.06 | 123.78 | 115.51 | 152.52 |
| Inventory Days | 64.44 | 112.51 | 119.36 | 174.35 | 168.24 | 127.72 | 138.71 | 126.64 |
| Days Payable | 43.11 | 38.76 | 104.70 | 119.86 | 138.51 | 88.18 | 75.97 | 104.03 |
| Cash Conversion Cycle | 130.02 | 208.39 | 195.93 | 205.31 | 212.79 | 163.33 | 178.25 | 175.13 |
| Working Capital Days | 129.43 | 108.29 | 124.03 | 111.49 | 147.05 | 116.60 | 129.04 | 135.78 |
| ROCE % | 17.69% | 14.27% | 11.22% | 6.93% | 10.07% | 9.62% | 8.27% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.43 | 1.39 | 1.44 | 0.55 | 1.59 |
| Diluted EPS (Rs.) | 1.43 | 1.39 | 1.44 | 0.59 | 1.59 |
| Cash EPS (Rs.) | 1.78 | 1.81 | 1.80 | 0.81 | 1.92 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 25.61 | 24.19 | 22.81 | 21.45 | 19.54 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 25.61 | 24.19 | 22.81 | 21.45 | 19.54 |
| Revenue From Operations / Share (Rs.) | 58.01 | 55.33 | 57.07 | 44.87 | 62.64 |
| PBDIT / Share (Rs.) | 3.21 | 3.68 | 3.80 | 2.49 | 4.76 |
| PBIT / Share (Rs.) | 2.86 | 3.26 | 3.43 | 2.23 | 4.43 |
| PBT / Share (Rs.) | 1.94 | 1.93 | 2.01 | 0.82 | 2.36 |
| Net Profit / Share (Rs.) | 1.43 | 1.39 | 1.44 | 0.54 | 1.59 |
| PBDIT Margin (%) | 5.52 | 6.64 | 6.66 | 5.55 | 7.60 |
| PBIT Margin (%) | 4.93 | 5.89 | 6.01 | 4.96 | 7.08 |
| PBT Margin (%) | 3.33 | 3.48 | 3.52 | 1.83 | 3.76 |
| Net Profit Margin (%) | 2.46 | 2.51 | 2.51 | 1.22 | 2.54 |
| Return on Networth / Equity (%) | 5.58 | 5.75 | 6.30 | 2.56 | 8.14 |
| Return on Capital Employeed (%) | 10.49 | 12.96 | 13.89 | 9.06 | 17.68 |
| Return On Assets (%) | 2.86 | 3.13 | 3.09 | 1.09 | 2.69 |
| Long Term Debt / Equity (X) | 0.05 | 0.03 | 0.07 | 0.13 | 0.25 |
| Total Debt / Equity (X) | 0.33 | 0.39 | 0.44 | 0.55 | 0.98 |
| Asset Turnover Ratio (%) | 1.23 | 1.22 | 1.18 | 0.96 | 1.13 |
| Current Ratio (X) | 2.03 | 2.06 | 1.90 | 1.76 | 1.59 |
| Quick Ratio (X) | 1.25 | 1.10 | 1.12 | 1.07 | 0.86 |
| Inventory Turnover Ratio (X) | 3.20 | 2.86 | 2.81 | 2.21 | 3.22 |
| Interest Coverage Ratio (X) | 3.47 | 2.76 | 2.68 | 1.78 | 2.29 |
| Interest Coverage Ratio (Post Tax) (X) | 2.55 | 2.04 | 2.01 | 1.39 | 1.83 |
| Enterprise Value (Cr.) | 33.89 | 60.21 | 36.79 | 54.94 | 0.00 |
| EV / Net Operating Revenue (X) | 0.40 | 0.75 | 0.44 | 0.84 | 0.00 |
| EV / EBITDA (X) | 7.33 | 11.34 | 6.71 | 15.26 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.28 | 0.59 | 0.29 | 0.61 | 0.00 |
| Price / BV (X) | 0.65 | 1.36 | 0.73 | 1.28 | 0.00 |
| Price / Net Operating Revenue (X) | 0.28 | 0.59 | 0.29 | 0.61 | 0.00 |
| EarningsYield | 0.08 | 0.04 | 0.08 | 0.02 | 0.00 |
After reviewing the key financial ratios for Adeshwar Meditex Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 5. It has increased from 1.39 (Mar 24) to 1.43, marking an increase of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 5. It has increased from 1.39 (Mar 24) to 1.43, marking an increase of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.78. This value is below the healthy minimum of 3. It has decreased from 1.81 (Mar 24) to 1.78, marking a decrease of 0.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.61. It has increased from 24.19 (Mar 24) to 25.61, marking an increase of 1.42.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.61. It has increased from 24.19 (Mar 24) to 25.61, marking an increase of 1.42.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 58.01. It has increased from 55.33 (Mar 24) to 58.01, marking an increase of 2.68.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.21. This value is within the healthy range. It has decreased from 3.68 (Mar 24) to 3.21, marking a decrease of 0.47.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.86. This value is within the healthy range. It has decreased from 3.26 (Mar 24) to 2.86, marking a decrease of 0.40.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.94. This value is within the healthy range. It has increased from 1.93 (Mar 24) to 1.94, marking an increase of 0.01.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 2. It has increased from 1.39 (Mar 24) to 1.43, marking an increase of 0.04.
- For PBDIT Margin (%), as of Mar 25, the value is 5.52. This value is below the healthy minimum of 10. It has decreased from 6.64 (Mar 24) to 5.52, marking a decrease of 1.12.
- For PBIT Margin (%), as of Mar 25, the value is 4.93. This value is below the healthy minimum of 10. It has decreased from 5.89 (Mar 24) to 4.93, marking a decrease of 0.96.
- For PBT Margin (%), as of Mar 25, the value is 3.33. This value is below the healthy minimum of 10. It has decreased from 3.48 (Mar 24) to 3.33, marking a decrease of 0.15.
- For Net Profit Margin (%), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 5. It has decreased from 2.51 (Mar 24) to 2.46, marking a decrease of 0.05.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.58. This value is below the healthy minimum of 15. It has decreased from 5.75 (Mar 24) to 5.58, marking a decrease of 0.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.49. This value is within the healthy range. It has decreased from 12.96 (Mar 24) to 10.49, marking a decrease of 2.47.
- For Return On Assets (%), as of Mar 25, the value is 2.86. This value is below the healthy minimum of 5. It has decreased from 3.13 (Mar 24) to 2.86, marking a decrease of 0.27.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.05, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.33. This value is within the healthy range. It has decreased from 0.39 (Mar 24) to 0.33, marking a decrease of 0.06.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.23. It has increased from 1.22 (Mar 24) to 1.23, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 2.03. This value is within the healthy range. It has decreased from 2.06 (Mar 24) to 2.03, marking a decrease of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 1.25. This value is within the healthy range. It has increased from 1.10 (Mar 24) to 1.25, marking an increase of 0.15.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.20. This value is below the healthy minimum of 4. It has increased from 2.86 (Mar 24) to 3.20, marking an increase of 0.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.47. This value is within the healthy range. It has increased from 2.76 (Mar 24) to 3.47, marking an increase of 0.71.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.55. This value is below the healthy minimum of 3. It has increased from 2.04 (Mar 24) to 2.55, marking an increase of 0.51.
- For Enterprise Value (Cr.), as of Mar 25, the value is 33.89. It has decreased from 60.21 (Mar 24) to 33.89, marking a decrease of 26.32.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.40, marking a decrease of 0.35.
- For EV / EBITDA (X), as of Mar 25, the value is 7.33. This value is within the healthy range. It has decreased from 11.34 (Mar 24) to 7.33, marking a decrease of 4.01.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.28, marking a decrease of 0.31.
- For Price / BV (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has decreased from 1.36 (Mar 24) to 0.65, marking a decrease of 0.71.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.28, marking a decrease of 0.31.
- For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.08, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Adeshwar Meditex Ltd:
- Net Profit Margin: 2.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.49% (Industry Average ROCE: 13.22%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.58% (Industry Average ROE: 10.35%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.55
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.25
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 11.5 (Industry average Stock P/E: 25.03)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.33
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.46%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | Gala 111 Lok Centre, MarolMaroshi Road, Mumbai Maharashtra 400059 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Abhinandan Nagaraja Rao | Chairman & Wholetime Director |
| Ms. Ashalata Baburao Raut | Managing Director |
| Mr. Krishnojirao Nagaraja Rao | Whole Time Director |
| Mr. Shailesh Vinayak Rajpure | Executive Director |
| Mr. Benegal Parameshwara Udpa | Ind. Non-Executive Director |
| Mr. Arun Koli | Ind. Non-Executive Director |
| Mr. Prithvi Sanjay Singh | Non Executive Director |
FAQ
What is the intrinsic value of Adeshwar Meditex Ltd?
Adeshwar Meditex Ltd's intrinsic value (as of 28 December 2025) is 13.50 which is 18.67% lower the current market price of 16.60, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 23.9 Cr. market cap, FY2025-2026 high/low of 26.5/14.0, reserves of ₹23.26 Cr, and liabilities of 62.70 Cr.
What is the Market Cap of Adeshwar Meditex Ltd?
The Market Cap of Adeshwar Meditex Ltd is 23.9 Cr..
What is the current Stock Price of Adeshwar Meditex Ltd as on 28 December 2025?
The current stock price of Adeshwar Meditex Ltd as on 28 December 2025 is 16.6.
What is the High / Low of Adeshwar Meditex Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Adeshwar Meditex Ltd stocks is 26.5/14.0.
What is the Stock P/E of Adeshwar Meditex Ltd?
The Stock P/E of Adeshwar Meditex Ltd is 11.5.
What is the Book Value of Adeshwar Meditex Ltd?
The Book Value of Adeshwar Meditex Ltd is 26.1.
What is the Dividend Yield of Adeshwar Meditex Ltd?
The Dividend Yield of Adeshwar Meditex Ltd is 0.00 %.
What is the ROCE of Adeshwar Meditex Ltd?
The ROCE of Adeshwar Meditex Ltd is 8.27 %.
What is the ROE of Adeshwar Meditex Ltd?
The ROE of Adeshwar Meditex Ltd is 5.51 %.
What is the Face Value of Adeshwar Meditex Ltd?
The Face Value of Adeshwar Meditex Ltd is 10.0.